Summary
The administration of cytosine arabinoside (araC) by continuous IV infusion requires the patient to be in hospital and have prolonged IV cannulation. In this study the pharmacokinetics of araC during continuous IV infusion were compared with those of continuous SC infusion in six patients with acute myelogenous leukaemia. Each patient acted as his own control. The mean plasma levels of araC reached a plateau within 2 h and the plasma concentrations and the area under the curve were similar for both methods of administration. The mean area under the curve (AUC) was 1147±230 ng/ml for the IV infusion and 1017±238 ng/ml for the SC infusion. The plasma araC concentrations showed wide interpatient variation, and there was also considerable variability in the plasma concentrations of araC within the individual patients after a plateau had apparently been reached.
Subcutaneous infusion was well tolerated by the patients without any local discomfort or excoriation and SC infusion of araC is thus a feasible alternative to IV infusion. It allows the patients the benefits of being at home, while avoiding unnecessary thrombophlebitis.
Similar content being viewed by others
References
Bodey GP, Freireich EJ, Monto RW, Hewlett JS (1969) Cytosine arabinoside (NSC-63878) therapy for acute leukaemia in adults. Cancer Chemother Rep [1] 53: 59–66
Culbertson JW, Wilkins RW, Ingelfinger FJ, Bradley SE (1951) The effect of upright posture on hepatic blood flow in normotensive and hypertensive subjects. J Clin Invest 30: 305–311
Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ, Grahame-Smith DG (1979) Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia Br J Clin Pharmacol 8: 219–227
Jeffreys DB, Pickup JC, Haw CM, Keen H (1979) Subcutaneous desferrioxamine infusion for haemachromatosis. Lancet II: 1364–1365
McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ (1981) Chemoimmunotherapy for adult acute leukaemia. Cancer 47: 1256
Piall EM, Aherne GW, Marks VM (1979) A radioimmunoassay for cytosine arabinoside. Br J Cancer 40: 548–554
Pickup JC, Keen H (1980) Continuous subcutaneous insulin infusion: A developing tool in diabetes research. Diabetologia 18: 1–4
Slevin ML, Piall EM, Aherne GW, Johnston A, Lister TA (1981) The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br J Clin Pharmacol 12: 507–510
South-West Oncology Group (1974) Cytarabine for acute leukaemia in adults. Effect of schedule on therapeutic response. Arch Intern Med 133: 251–259
Weinstein H, Griffin T, Cohen H, Proper RD, Sallan S (1978) Pharmacology of cytosine arabinoside (a-c). Proc Am Assoc Cancer Res 19: 157
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E II (1980) Treatment of acute myelogenous leukaemia in children and adults. N Engl J Med 303: 473
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Exp Ther 18: 377–390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Slevin, M.L., Piall, E.M., Aherne, G.W. et al. Subcutaneous infusion of cytosine arabinoside. Cancer Chemother. Pharmacol. 10, 112–114 (1983). https://doi.org/10.1007/BF00446221
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00446221